Modified Lung-RADS classification incorporating nodule risk calculator.
The ACR Lung Screening Reporting and Data System (Lung-RADS) classification system, which incorporates nodule characteristics (solid, part-solid, and nonsolid) in addition to size, has been widely adopted in the United States. Nodule risk calculators have been used for many years in the clinical setting and can also be applied to the screening environment. The Pan-Canadian Early Detection of Lung Cancer (PanCan) nodule risk calculator was developed and validated specifically in the LDCT screening setting and has performed favorably in retrospective comparisons with other approaches.
Our work and others has suggested that each of these 2 approaches have advantages and shortcomings. For example, Lung-RADS classifies as higher risk many mid-size lung nodules calculated to be of <5% cancer risk while PanCan classifies many ground glass lesions as high risk, even if most are indolent and do not require immediate action. Local data suggest that early recall investigations after a baseline screen could be reduced by 1/3 if a hybrid system incorporating Lung-RADS categories and PanCan calculator without loss of sensitivity for cancer (J Am Coll Radiol 2019 Oct;16(10):1425-1432).
We aim to apply a modified Lung-RADS classification system which incorporates the PanCan calculator in an independent set of baseline LDCT examinations. All baseline scans with available information to apply the Lung-RADS v1.1 classification and calculate highest nodule risk with the PanCan calculator will be selected for analysis.
The following metrics will be compared between the Lung-RADS v1.1 classification and the hybrid Lung-RADS system incorporating the PanCan calculator.
1. Distribution of scans across categories
2. Early recall rate (#Category 3 or greater scans/total number of scans)
3. False negative rate (#Category 2 or lower scan with diagnosis of cancer or lesion growth within 18 months/#Category 2 scans or lower)
4. False discovery rate (Category 3 or greater scans without a diagnosis of cancer of lesion growth within 18 months / #Category 3 or greater scans)
5. False positive rate (Category 3 or greater scans without a diagnosis of cancer of lesion growth within 18 months / total number of scans)
A sensitivity analysis will also be performed to assess the impact of changing Category 2 & 3 PanCan cutoffs for solid, semi-solid and ground glass nodules on the above.
Dr. Paul MacEachern, University of Calgary
Dr. Mike Bristow, University of Calgary
Dr. Eric Bedard, University of Alberta